106 related articles for article (PubMed ID: 27522526)
21. Fabrication of self-assembled (-)-epigallocatechin gallate (EGCG) ovalbumin-dextran conjugate nanoparticles and their transport across monolayers of human intestinal epithelial Caco-2 cells.
Li Z; Gu L
J Agric Food Chem; 2014 Feb; 62(6):1301-9. PubMed ID: 24446922
[TBL] [Abstract][Full Text] [Related]
22. Ability of a salivary intrinsically unstructured protein to bind different tannin targets revealed by mass spectrometry.
Canon F; Giuliani A; Paté F; Sarni-Manchado P
Anal Bioanal Chem; 2010 Sep; 398(2):815-22. PubMed ID: 20665010
[TBL] [Abstract][Full Text] [Related]
23. Synergistic effects of negatively charged hydrophobic nanoparticles and (-)-epigallocatechin-3-gallate on inhibiting amyloid β-protein aggregation.
Liu H; Yu L; Dong X; Sun Y
J Colloid Interface Sci; 2017 Apr; 491():305-312. PubMed ID: 28049055
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, structure analyses, and characterization of novel epigallocatechin gallate (EGCG) glycosides using the glucansucrase from Leuconostoc mesenteroides B-1299CB.
Moon YH; Lee JH; Ahn JS; Nam SH; Oh DK; Park DH; Chung HJ; Kang S; Day DF; Kim D
J Agric Food Chem; 2006 Feb; 54(4):1230-7. PubMed ID: 16478241
[TBL] [Abstract][Full Text] [Related]
25. Validation of a high performance liquid chromatography method for the stabilization of epigallocatechin gallate.
Fangueiro JF; Parra A; Silva AM; Egea MA; Souto EB; Garcia ML; Calpena AC
Int J Pharm; 2014 Nov; 475(1-2):181-90. PubMed ID: 25175728
[TBL] [Abstract][Full Text] [Related]
26. Electrospun zein fibers as carriers to stabilize (-)-epigallocatechin gallate.
Li Y; Lim LT; Kakuda Y
J Food Sci; 2009 Apr; 74(3):C233-40. PubMed ID: 19397708
[TBL] [Abstract][Full Text] [Related]
27. Relationship between the biological activities of methylated derivatives of (-)-epigallocatechin-3-O-gallate (EGCG) and their cell surface binding activities.
Yano S; Fujimura Y; Umeda D; Miyase T; Yamada K; Tachibana H
J Agric Food Chem; 2007 Aug; 55(17):7144-8. PubMed ID: 17661493
[TBL] [Abstract][Full Text] [Related]
28. Molecular Capture Using the Precipitate of Creaming-Down by (-)-Epigallocatechin-3-O-gallate.
Tsutsumi H; Sato A; Fujino S; Fujioka Y; Ishizu T
Chem Pharm Bull (Tokyo); 2019; 67(5):501-504. PubMed ID: 31061378
[TBL] [Abstract][Full Text] [Related]
29. Coencapsulation and Stability Evaluation of Hydrophilic and Hydrophobic Bioactive Compounds in a Cagelike Phytoferritin.
Meng D; Shi L; Zhu L; Wang Q; Liu J; Kong Y; Hou M; Yang R; Zhou Z
J Agric Food Chem; 2020 Mar; 68(10):3238-3249. PubMed ID: 32059106
[TBL] [Abstract][Full Text] [Related]
30. Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells.
Hong J; Lu H; Meng X; Ryu JH; Hara Y; Yang CS
Cancer Res; 2002 Dec; 62(24):7241-6. PubMed ID: 12499265
[TBL] [Abstract][Full Text] [Related]
31. Real Time Monitoring of Inhibition of Adipogenesis and Angiogenesis by (-)-Epigallocatechin-3-Gallate in 3T3-L1 Adipocytes and Human Umbilical Vein Endothelial Cells.
Tang W; Song H; Cai W; Shen X
Nutrients; 2015 Oct; 7(10):8871-86. PubMed ID: 26516907
[TBL] [Abstract][Full Text] [Related]
32. LNCaP cells exposed to ceramic drug delivery treatment with epigallocatechin-3-gallate, thymoquinone, and tannic acid.
Richards LR; Jones P; Hughes J; Benghuzzi H; Tucci M
Biomed Sci Instrum; 2007; 43():242-7. PubMed ID: 17487088
[TBL] [Abstract][Full Text] [Related]
33. An in vitro evaluation of epigallocatechin gallate (eGCG) as a biocompatible inhibitor of ricin toxin.
Dyer PD; Kotha AK; Gollings AS; Shorter SA; Shepherd TR; Pettit MW; Alexander BD; Getti GT; El-Daher S; Baillie L; Richardson SC
Biochim Biophys Acta; 2016 Jul; 1860(7):1541-50. PubMed ID: 27017946
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Myeloperoxidase- and Neutrophil-Mediated Hypochlorous Acid Formation in Vitro and Endothelial Cell Injury by (-)-Epigallocatechin Gallate.
Tian R; Ding Y; Peng YY; Lu N
J Agric Food Chem; 2017 Apr; 65(15):3198-3203. PubMed ID: 28361543
[TBL] [Abstract][Full Text] [Related]
35. Chitosan nanoparticles enhance the plasma exposure of (-)-epigallocatechin gallate in mice through an enhancement in intestinal stability.
Dube A; Nicolazzo JA; Larson I
Eur J Pharm Sci; 2011 Oct; 44(3):422-6. PubMed ID: 21925598
[TBL] [Abstract][Full Text] [Related]
36. Encapsulation of (-)-epigallocatechin gallate into liposomes and into alginate or chitosan microparticles reinforced with liposomes.
Istenič K; Cerc Korošec R; Poklar Ulrih N
J Sci Food Agric; 2016 Oct; 96(13):4623-32. PubMed ID: 26921243
[TBL] [Abstract][Full Text] [Related]
37. Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs.
Nkansah P; Antipas A; Lu Y; Varma M; Rotter C; Rago B; El-Kattan A; Taylor G; Rubio M; Litchfield J
J Control Release; 2013 Jul; 169(1-2):150-61. PubMed ID: 23570985
[TBL] [Abstract][Full Text] [Related]
38. The interactions of epigallocatechin-3-gallate with human whole saliva and parotid saliva.
Yao JW; Lin CJ; Chen GY; Lin F; Tao T
Arch Oral Biol; 2010 Jul; 55(7):470-8. PubMed ID: 20593553
[TBL] [Abstract][Full Text] [Related]
39. Correlation of hydrotropic solubilization by urea with logD of drug molecules and utilization of this effect for topical formulations.
Herbig ME; Evers DH
Eur J Pharm Biopharm; 2013 Sep; 85(1):158-60. PubMed ID: 23958327
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of Creaming Down Based on Chemical Characterization of a Complex of Caffeine and Tea Catechins.
Ishizu T; Tsutsumi H; Sato T
Chem Pharm Bull (Tokyo); 2016; 64(7):676-86. PubMed ID: 27373623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
